prostate-cancer

Documents about prostate-cancer

• Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate Cancer#832896ClinicalTrials.gov
• Insulin Resistance Following ADT for Prostate CA#831299ClinicalTrials.gov
• Assessment of Research Digest Impact for Minority with Prostate Cancer, MiCAP Phase III Study#843401ClinicalTrials.gov
• PSMA-PET Registry for Recurrent Prostate Cancer#825094ClinicalTrials.gov
• Impact of androgen receptor pathway inhibitors on cognitive function in older adults treated for metastatic prostate cancer#257416HAL (France)
• Urinary miR-191-5p levels are significantly reduced after radical prostatectomy in patients with prostate cancer#262141HAL (France)
• Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy#478501Europe PMC
• Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer#633723ClinicalTrials.gov
• A Multi-modal, Physician-centered Intervention to Improve Guideline-concordant Prostate Cancer Imaging#834216ClinicalTrials.gov
• Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer#836209ClinicalTrials.gov
• Feasibility of a Remotely-Delivered Resistance Training Program for Cognitive Function in Men Living With and Beyond Prostate Cancer#803239ClinicalTrials.gov
• Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy in Early Stage, Low Volume Prostate Cancer#841515ClinicalTrials.gov
• Focal radiotherapy improves CAR T cell therapy targeting prostate cancer#417339bioRxiv / medRxiv
• INSM1 Regulates Neuroendocrine Plasticity and Tumor Progression in Prostate Cancer#610862bioRxiv / medRxiv
• Figure 1 from DGAT1 Drives Racially Divergent Fibroblast Activation via ERK1/2-Dependent Tumorigenic Signaling in Prostate Cancer#253435Figshare
• Figure 2 from DGAT1 Drives Racially Divergent Fibroblast Activation via ERK1/2-Dependent Tumorigenic Signaling in Prostate Cancer#253436Figshare
• Figure 3 from DGAT1 Drives Racially Divergent Fibroblast Activation via ERK1/2-Dependent Tumorigenic Signaling in Prostate Cancer#253437Figshare
• Figure 4 from DGAT1 Drives Racially Divergent Fibroblast Activation via ERK1/2-Dependent Tumorigenic Signaling in Prostate Cancer#253438Figshare
• Figure 5 from DGAT1 Drives Racially Divergent Fibroblast Activation via ERK1/2-Dependent Tumorigenic Signaling in Prostate Cancer#253439Figshare
• Figure 6 from DGAT1 Drives Racially Divergent Fibroblast Activation via ERK1/2-Dependent Tumorigenic Signaling in Prostate Cancer#253440Figshare
• Figure S1 from DGAT1 Drives Racially Divergent Fibroblast Activation via ERK1/2-Dependent Tumorigenic Signaling in Prostate Cancer#253441Figshare
• Figure S2 from DGAT1 Drives Racially Divergent Fibroblast Activation via ERK1/2-Dependent Tumorigenic Signaling in Prostate Cancer#253442Figshare
• Table S1 from DGAT1 Drives Racially Divergent Fibroblast Activation via ERK1/2-Dependent Tumorigenic Signaling in Prostate Cancer#253443Figshare
• Table S2 from DGAT1 Drives Racially Divergent Fibroblast Activation via ERK1/2-Dependent Tumorigenic Signaling in Prostate Cancer#253444Figshare
• Prostate Radiotherapy Integrated With Simultaneous MRI (The PRISM Study)#842944ClinicalTrials.gov
• Loneliness in prostate cancer survivors.#284906NCBI PubMed Central
• RNActive®-Derived Therapeutic Vaccine#454066ClinicalTrials.gov
• Neuroscience in prostate cancer#676476Europe PMC
• PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.#842615ClinicalTrials.gov
• Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer#160359ClinicalTrials.gov
• Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer#272415ClinicalTrials.gov
• A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy#366553ClinicalTrials.gov
• Cost Efficacy Evaluation of Robot Assisted Radical Prostatectomy#806837ClinicalTrials.gov
• Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer#812622ClinicalTrials.gov
• SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer#826354ClinicalTrials.gov
• The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC#828407ClinicalTrials.gov
• A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer#836501ClinicalTrials.gov
• MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness#837865ClinicalTrials.gov
• Calcitriol in Preventing Prostate Cancer in Patients With Prostatic Intraepithelial Neoplasia#839084ClinicalTrials.gov
• Trial of Print Messages to Support the Role of Partners in Promoting Provider Discussions About Prostate Cancer Screening Among AA Men#829188ClinicalTrials.gov
• Prostate Cancer Genius App Education and Home-based PSA Screening for African American Men#840220ClinicalTrials.gov
• PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer#811270ClinicalTrials.gov
• Comparing Transperineal to Transrectal MRI-US Fusion Prostate Biopsy#828075ClinicalTrials.gov
• Radical Prostatectomy Without Prostate Biopsy Following PSMA PET/CT Based on Diagnostic Model#835275ClinicalTrials.gov
• QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA#146479ClinicalTrials.gov
• DISCO: A Patient Intervention to Reduce the Financial Burden of Cancer#424195ClinicalTrials.gov
• Ethnographic Study of the Everyday Life of Men With Prostate Cancer, Focusing on Diet, Activities and Digital Behavior#833681ClinicalTrials.gov
• Effectiveness Evaluation of a Self-management Program for Prostate Cancer Survivors#841970ClinicalTrials.gov
• Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients#201613ClinicalTrials.gov
• Deep learning applied to cancer prostate histology slides : diagnosis, prediction of bio-chemical recurrence and genetic mutations#179409HAL (France)